UCL and UCLH reported follow-up results from the NEOPRISM-CRC trial testing a short course of immunotherapy before surgery for a subset of bowel cancer patients. The update highlighted zero relapses in the reported outcome set, suggesting a strong early disease-control signal for preoperative immunotherapy. The approach is built around giving immunotherapy prior to surgical intervention, with the intent to influence residual disease biology and post-surgery outcomes. The report adds to prior clinical discussion around neoadjuvant immunotherapy strategies and the search for response predictors. UCLH framed the findings as potentially practice-relevant for patients eligible for the trial regimen, while the broader field continues to await larger cohorts and longer-term confirmation.